Form 4 for BBIO BridgeBio Pharma, Inc.
Accepted 2026-05-19 16:30:14 ET · period of report 2026-05-16 · accession 0001470831-26-000473 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-05-19 16:30 | 2026-05-16 | BBIO | Trimarchi Thomas | Pres, CFO | F - Tax | $66.13 | -22.8K | 372.8K | -6% | -$1.51M |
| MT | 2026-05-19 16:30 | 2026-05-18 | BBIO | Trimarchi Thomas | Pres, CFO | S - Sale | $65.08 | -13.7K | 359.2K | -4% | -$888.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-16 | F | D | 22,781 | $66.13 | 372,845 | D | — | — | (F1) Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 41,193 shares of Common Stock underlying the Reporting Person's RSUs. |
| 2 | Common | Common Stock | 2026-05-18 | S | D | 10,456 | $64.82 | 362,389 | D | — | — | (F2) This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. (F3) Represents the weighted average sale price of the shares sold from $64.34 to $65.33 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2026-05-18 | S | D | 3,195 | $65.95 | 359,194 | D | — | — | (F2) This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. (F4) Represents the weighted average sale price of the shares sold from $65.54 to $66.21 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |